Why Amarin Stock Skyrocketed Today
Shares of (NASDAQ: AMRN) skyrocketed 32.9% on Wednesday after the biopharmaceutical company announced strong preliminary fiscal fourth-quarter results, a new share-repurchase authorization, and encouraging 2024 guidance.
In a press release this morning, Amarin told investors it now expects fourth-quarter 2023 revenue of between $72 million and $74 million, far above analysts' consensus estimates for sales closer to $62 million. That would bring full-year 2023 revenue to between $304 million and $306 million, versus estimates for $294 million.
Amarin says it ended the year with roughly $321 million in cash and investments, with positive cash flow of $10 million for the year. That marks the company's sixth straight quarter of cash-positive or cash-neutral operations.
Source Fool.com
Amarin Corp. ADR Aktie
Aufgrund von 1 Buy-Einschätzungen und 2 Sell-Einschätzungen ist die Stimmung bezüglich der Amarin Corp. ADR Aktie ziemlich ausgeglichen.
